Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms

Autor: Zhuoer Xie, Evan C. Chen, Lourdes M. Mendez, Rami Komrokji, Amer M. Zeidan

Publikováno v: The Cancer Journal. 29:130-137

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de3e64dd509bfa9d88d7ebf5cbc87ca8
https://doi.org/10.1097/ppo.0000000000000656

The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy

Autor: Lourdes M. Mendez, Ryan R. Posey, Pier Paolo Pandolfi

Publikováno v: Frontiers in Oncology, Vol 9 (2019)

AML holds a unique place in the history of immunotherapy by virtue of being among the first malignancies in which durable remissions were achieved with “adoptive immunotherapy,” now known as allogeneic stem cell transplantation. The successful de

Externí odkaz: https://doaj.org/article/4b3e65fc26b74d8abdd94e73992eaef7

Supplementary Table 1 from Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms

Autor: Jeffrey I. Zwicker, Robert Flaumenhaft, Lourdes M. Mendez, Alexandra Barr, Thomas Bogue, Anish V. Sharda

Details of the thromboembolic events in the study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6891f00ae8176e9a0fffa3a0fb3371b7
https://doi.org/10.1158/1078-0432.22480170

Supplementary Figure 3 from Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms

Autor: Jeffrey I. Zwicker, Robert Flaumenhaft, Lourdes M. Mendez, Alexandra Barr, Thomas Bogue, Anish V. Sharda

Comparison of standard thrombosis risk factors with plasma PDI and development of thromboembolic events in MPN

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7750b936070c50ad1dde0bfe2b7db11
https://doi.org/10.1158/1078-0432.22480173.v1

AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and reduced infusion-related reactions

Autor: Naval Daver, Pau Montesinos, Ahmed Aribi, Giovanni Martinelli, Jessica K. Altman, Eunice S. Wang, Gail J. Roboz, Patrick W. Burke, Gianluca Gaidano, Roland B. Walter, Xavier Thomas, Deepa Jeyakumar, Daniel J. DeAngelo, Harry P. Erba, Elisabetta Todisco, Kebede Begna, Anjali Advani, Lauris Gastaud, Adolfo de la Fuente, Antonio Curti, Lourdes M. Mendez, Paresh Vyas, Nicolas Boissel, Norbert Vey, Christian Recher, Thomas Longval, Uwe Platzbecker, Silke Kapp-Schwörer, Christoph Schliemann, Marina Konopleva, Laura Torres, David A. Sallman, Guido Marcucci, Giovanni Marconi, Hagop Kantarjian, Callum M. Sloss, Karen E. Malcolm, Patrick A. Zweidler-McKay, Kendra Sweet

Publikováno v: Clinical lymphoma, myeloma & leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Context: Pivekimab sunirine (PVEK, IMGN632) is a first-in-class ADC comprising a CD123 high-affinity antibody, a cleavable linker, and an IGN (indolinobenzodiazepine pseudodimer) payload. PVEK with azacitidine (AZA) and venetoclax (VEN) is a novel tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b19eb722a14bf739d2edadca607852a
https://doi.org/10.1016/s2152-2650(22)01257-5